New Candidates for Furin Inhibition as Probable Treat for COVID-19: Docking Output

  title={New Candidates for Furin Inhibition as Probable Treat for COVID-19: Docking Output},
  author={Mohammad Reza Dayer},
Furin is a serine protease that takes part in the processing and activation of the host cell pre-proteins. The enzyme also plays an important role in the activation of several viruses like the newly emerging SARS-CoV-2 virus that causes COVID-19 disease with a high rate of virulence and mortality. Unlike viral enzymes, furin owns a constant sequence and active site characteristics and seems to be a better target for drug design for COVID-19 treatment. Considering furin active site as receptor… Expand

Figures and Tables from this paper


Furin: A Potential Therapeutic Target for COVID-19
It is speculated that the presence of a redundant furin cut site in its Spike protein is responsible for SARS-CoV-2’s stronger infectious than other coronaviruses, which leads to higher membrane fusion efficiency. Expand
Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective
Docking experiments using the newly released coordinate structure for COVID-19 protease as a receptor and thoughtfully selected chemicals among antiviral and antibiotics drugs as ligands suggest the binding capacity and the inhibitory potency of candidates are as follows. Expand
Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence
The structure of Furin in complex with SARS-CoV-2 spike glycoprotein is reported, demonstrating how Furin binds to the S1/S2 region of spike glyCoprotein and eventually cleaves the viral protein using experimental functional studies, molecular dynamics, and docking. Expand
Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study
Background: The severe acute respiratory syndrome (SARS) is a life threatening viral infection caused by a positive, single stranded RNA virus from the enveloped coronaviruse family. Associated withExpand
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry. Expand
Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
Host proteases that proteolytically activate the SARS-CoV-2 spike protein, critical for its fusion after binding to angiotensin-converting enzyme 2 (ACE2), as antiviral targets are focused on. Expand
Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?
Whether azithromycin and clarithromyquin, the RNA-dependent RNA polymerase protein inhibitor used in the treatment of COVID-19, is effective against SARS Cov-2 in silico is determined. Expand
Therapeutic uses of furin and its inhibitors: a patent review
Despite considerable evidence of in vivo efficacy, limited confirmation from clinical trials supports or refutes the further use of these compounds in a therapeutic context. Expand
Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
It is suggested that nelfinavir might be a potential inhibitor against 2019-nCov Mpro, and built homology models based on SARS Mpro structures and docked 1903 small molecule drugs to the models. Expand
X-ray Structures of Human Furin in Complex with Competitive Inhibitors
This work presents a novel preparation of human furin and the first crystal structures of this enzyme in complex with noncovalent inhibitors, and shows the inhibitor exchange by soaking, allowing the investigation of additional inhibitors and substrate analogues. Expand